Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Healthcare
Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is... see more

Recent & Breaking News (CSE:RVV)

Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke

GlobeNewswire 9 days ago

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

GlobeNewswire October 31, 2024

Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures

GlobeNewswire September 18, 2024

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections

GlobeNewswire August 28, 2024

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

GlobeNewswire July 2, 2024

Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID

GlobeNewswire June 12, 2024

Revive Therapeutics Provides Update From FDA Meeting for Long COVID Diagnostic Product

GlobeNewswire June 10, 2024

This life sciences company is gearing up to treat long COVID

Jocelyn Aspa April 25, 2024

Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID

GlobeNewswire April 23, 2024

Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product

GlobeNewswire April 18, 2024

Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder

GlobeNewswire April 2, 2024

Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID

GlobeNewswire March 27, 2024

Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID

GlobeNewswire March 19, 2024

Revive Therapeutics Provides Corporate Update

GlobeNewswire March 12, 2024

Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110

GlobeNewswire February 26, 2024

Revive Therapeutics Explores the Use of Bucillamine for Long COVID

GlobeNewswire February 1, 2024

Revive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for Gross Proceeds of $913,500

GlobeNewswire January 31, 2024

Revive Therapeutics Ltd. Announces Offering of Up to $3 Million

GlobeNewswire January 24, 2024

Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada

GlobeNewswire January 16, 2024

Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine

GlobeNewswire January 10, 2024